On October 5, Axinn partner Chad Landmon participated in a panel entitled, "Identifying and Comprehending Pre-Commercialization Concerns Relative to Small Molecules and Biologics" at ACI’s Hatch-Waxman and BPCIA Virtual Proficiency Series.

This session examined the current pre-commercialization landscape and considerations in light of Health Care Reform.

Click here for more information.